Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Cellix launches second generation biochip

Cellix : 07 April, 2008  (New Product)
Cellix has launched the VenaEC Biochip, which is designed to enable researchers to execute physiologically relevant flow experiments evaluating the adhesion of suspension cells to an endothelial cell monolayer.
The VenaEC biochip is the second generation biochip to Cellix's Vena8 Biochip.

As with the first generation Vena8 Biochip, a wide range of suspension cell samples may be used with the VenaEC including T-cells, monocytes, neutrophils, eosinophils, platelets and whole blood (heparanized).

Compatible with both the VenaFlux and Microfluidic SP Platforms, the VenaEC Biochip can be used to produce IC50 curves under shear stress conditions mimicking physiological flow.

The Biochip is an important addition to Cellix's product portfolio offering scientists a robust cell-based Assay tool for drug discovery, particularly in lead optimisation studies and in parallel with animal models.

'The VenaEC Biochip gives researchers a physiological snap-shot of how a potential lead candidate will affect cells in a human capillary,' said Vivienne Williams, chief executive officer of Cellix. 'This is a robust in-vitro cell-based Assay that will give major pharmaceutical and biotechnology companies powerful data and a competitive edge on how their lead candidates will perform in clinical trials.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo